JP2008545145A - 対応治療抗体の有無を問わない標的抗原の検出 - Google Patents

対応治療抗体の有無を問わない標的抗原の検出 Download PDF

Info

Publication number
JP2008545145A
JP2008545145A JP2008519853A JP2008519853A JP2008545145A JP 2008545145 A JP2008545145 A JP 2008545145A JP 2008519853 A JP2008519853 A JP 2008519853A JP 2008519853 A JP2008519853 A JP 2008519853A JP 2008545145 A JP2008545145 A JP 2008545145A
Authority
JP
Japan
Prior art keywords
antibody
therapeutic antibody
target antigen
sample
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008519853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545145A5 (cg-RX-API-DMAC7.html
Inventor
レンツ，ヘルムート
ショイアー，ベルナー
ティアー，マルティナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2008545145A publication Critical patent/JP2008545145A/ja
Publication of JP2008545145A5 publication Critical patent/JP2008545145A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2008519853A 2005-07-06 2006-07-05 対応治療抗体の有無を問わない標的抗原の検出 Pending JP2008545145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP06004447 2006-03-06
PCT/EP2006/006524 WO2007003420A1 (en) 2005-07-06 2006-07-05 Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody

Publications (2)

Publication Number Publication Date
JP2008545145A true JP2008545145A (ja) 2008-12-11
JP2008545145A5 JP2008545145A5 (cg-RX-API-DMAC7.html) 2010-11-18

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008519853A Pending JP2008545145A (ja) 2005-07-06 2006-07-05 対応治療抗体の有無を問わない標的抗原の検出

Country Status (19)

Country Link
US (1) US20070009976A1 (cg-RX-API-DMAC7.html)
EP (2) EP2194380A3 (cg-RX-API-DMAC7.html)
JP (1) JP2008545145A (cg-RX-API-DMAC7.html)
KR (1) KR20080016939A (cg-RX-API-DMAC7.html)
AR (1) AR053948A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006265275A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0612591A2 (cg-RX-API-DMAC7.html)
CA (1) CA2613187A1 (cg-RX-API-DMAC7.html)
CR (1) CR9635A (cg-RX-API-DMAC7.html)
EC (1) ECSP088081A (cg-RX-API-DMAC7.html)
IL (1) IL188317A0 (cg-RX-API-DMAC7.html)
MA (1) MA29730B1 (cg-RX-API-DMAC7.html)
MX (1) MX2008000277A (cg-RX-API-DMAC7.html)
MY (1) MY157955A (cg-RX-API-DMAC7.html)
NO (1) NO20076662L (cg-RX-API-DMAC7.html)
NZ (1) NZ564471A (cg-RX-API-DMAC7.html)
RU (1) RU2008103608A (cg-RX-API-DMAC7.html)
TW (1) TWI312864B (cg-RX-API-DMAC7.html)
WO (1) WO2007003420A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001264696B2 (en) 2000-05-19 2007-01-04 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
ZA200701234B (en) * 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
US7936392B2 (en) 2004-10-01 2011-05-03 The Board Of Trustees Of The Leland Stanford Junior University Imaging arrangements and methods therefor
WO2007092545A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Variable imaging arrangements and methods therefor
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2596133C (en) 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
PT4403228T (pt) 2011-10-14 2025-10-07 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
US9815904B2 (en) 2013-04-16 2017-11-14 Genetech, Inc. Pertuzumab variants and evaluation thereof
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
PT3302551T (pt) 2015-05-30 2024-08-21 H Hoffnabb La Roche Ag Métodos de tratamento do cancro da mama metastático positivo para her2 não tratado previamente
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
US20180221481A1 (en) 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
LT3570884T (lt) 2017-01-17 2020-12-10 Genentech, Inc. Poodinės her2 antikūnų kompozicijos
JP6992081B2 (ja) 2017-03-02 2022-02-03 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳癌のアジュバント治療
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
MX2022015884A (es) 2020-06-29 2023-04-03 Genentech Inc Combinacion de dosis fija de pertuzumab mas trastuzumab.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024993A2 (en) * 2001-09-20 2003-03-27 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
CN101412758A (zh) 1996-10-18 2009-04-22 基因技术股份有限公司 抗ErbB2抗体
AU2003273218C1 (en) * 2002-07-15 2019-01-17 F. Hoffmann - La Roche Ag Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024993A2 (en) * 2001-09-20 2003-03-27 Board Of Regents, The University Of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays

Also Published As

Publication number Publication date
EP1902315A1 (en) 2008-03-26
CA2613187A1 (en) 2007-01-11
AR053948A1 (es) 2007-05-23
MX2008000277A (es) 2008-03-24
KR20080016939A (ko) 2008-02-22
CR9635A (es) 2008-02-20
MY157955A (en) 2016-08-30
NZ564471A (en) 2010-04-30
US20070009976A1 (en) 2007-01-11
ECSP088081A (es) 2008-02-20
NO20076662L (no) 2008-04-03
AU2006265275A1 (en) 2007-01-11
MA29730B1 (fr) 2008-09-01
EP2194380A3 (en) 2010-07-14
BRPI0612591A2 (pt) 2010-11-23
EP2194380A2 (en) 2010-06-09
TW200741203A (en) 2007-11-01
WO2007003420A1 (en) 2007-01-11
IL188317A0 (en) 2008-04-13
RU2008103608A (ru) 2009-08-20
TWI312864B (en) 2009-08-01

Similar Documents

Publication Publication Date Title
JP2008545145A (ja) 対応治療抗体の有無を問わない標的抗原の検出
US7279287B2 (en) Analytical method
CN110383068A (zh) 评估患者样品中uch-l1状态的改进方法
CN102625915A (zh) 糖蛋白质的测定方法、肝病的检查方法、糖蛋白质定量用试剂及肝病病情指标糖链标记糖蛋白质
JP2011039072A (ja) 実験動物における治療抗体の検出
US20180113127A1 (en) Immunoassay method and assay reagent used in said method
US20110040544A1 (en) Systems And Methods For Treating, Diagnosing And Predicting The Response To Therapy Of Breast Cancer
JP6660932B2 (ja) Ｌ−ｆａｂｐの免疫学的測定方法及び該方法に用いられる測定試薬
EP2707720B1 (en) Diagnosis and prognosis of triple negative breast and ovarian cancer
CN118515772A (zh) 抗生物素单克隆抗体及其制备方法和应用
CN101213450A (zh) 不论存在或不存在相对应的治疗用抗体而检测靶抗原
Fetsch et al. The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature
HK1115446A (en) Detecting of a target antigen irrespective of the presenace or absence of a corresponding therapeutic antibody
WO2016118531A1 (en) Methods and kits for analysis of hmgb1 isoforms
US20250044284A1 (en) Materials and methods for enhanced detection and screening of molecules of therapeutic potential
WO2023191046A1 (ja) Ｈｒｇに対するモノクローナル抗体を用いたｈｒｇの測定方法
KR20240051109A (ko) 검정 신호 증폭을 위한 방법, 조성물 및 키트
CN119371525A (zh) 抗甲状腺球蛋白抗体、试剂盒和用途
CN120513252A (zh) 环孢菌素-吖啶酯及其制备和使用方法
Ahmed Elucidation of the Principles

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100629

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111101